Back to search

Article

Effects of the ABCG2 C421A Polymorphism on Plasma Gefitinib Concentration

2019-07-05

Abstract excerpt

<h4>Background: </h4> In patients with epidermal growth factor (EGFR) exon 21 L858R mutation-positive non-small cell lung cancer (NSCLC) treated with gefitinib, we found that a lower plasma gefitinib concentration was associated with shorter progression-free survival (PFS). ATP-binding castle protein G2 (ABCG2) is considered to inhibit the activities of certain gefitinib transporters, which affects drug pharmacoki...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
4ac84ff3-219e-56ba-a774-aac7f8ed9b90
DOI
10.21203/rs.2.10916/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Effects of the ABCG2 C421A Polymorphism on Plasma Gefitinib ConcentrationDOI 10.21203/rs.2.10916/v1
Select a neighboring publication to make it the new centre.